Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    pleural plaque OR pleural effusion OR asbestosis OR mesothelioma | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
1 Recruiting Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Condition: Mesothelioma
Intervention:
2 Recruiting Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: LMB-100
3 Recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Conditions: Advanced Peritoneal Malignant Mesothelioma;   Advanced Pleural Malignant Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Solid Neoplasm;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pleural Mesothelioma;   Thymoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium;   Other: Pharmacological Study
4 Recruiting Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma
Interventions: Radiation: Hypofractionated Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
5 Recruiting Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Conditions: Recurrent Pleural Malignant Mesothelioma;   Stage IV Pleural Mesothelioma
Intervention: Drug: Nintedanib
6 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
7 Recruiting Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Peritoneal Malignant Mesothelioma;   Pleural Biphasic Mesothelioma;   Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma;   Pleural Sarcomatoid Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
8 Recruiting Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Advanced Pleural Malignant Mesothelioma;   HLA-A*0201 Positive Cells Present;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pleural Malignant Mesothelioma;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pleural Mesothelioma
Interventions: Biological: Aldesleukin;   Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
9 Recruiting Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
Condition: Pleural Effusion
Interventions: Other: Manometry-guided thoracentesis;   Other: Symptom-guided thoracentesis
10 Recruiting Clinical and Histopathologic Characteristics of BAP1 Mutations
Conditions: Malignant Pleural Mesothelioma (MPM);   Choroidal Nevus;   Primary Uveal Melanoma (UM);   Metastatic Uveal Melanoma (UM);   Renal Cell Carcinoma;   Cholangiocarcinoma
Intervention: Other: tumor specimens
11 Recruiting Mithramycin for Lung, Esophagus, and Other Chest Cancers
Conditions: Lung Cancer;   Esophageal Cancer;   Mesothelioma;   Gastrointestinal Neoplasms;   Breast Cancer
Intervention: Drug: Mithramycin
12 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Intervention:
13 Recruiting CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Conditions: Cervical Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Mesothelioma;   Lung Cancer
Interventions: Drug: Fludarabine;   Biological: Anti-mesothelin CAR;   Drug: Cycolphosphamide;   Drug: Aldesleukin
14 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod
15 Recruiting Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Pulmonary Metastases From Cancers;   Mediastinal or Chest Wall Neoplasms;   Malignant Pleural Mesotheliomas NOS;   Esophageal Cancers NOS;   Lung Cancer NOS
Intervention:
16 Recruiting Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue
Conditions: Thymus Tumors;   Mesothelioma;   Non- Small Cell Lung Cancer;   Small Cell Lung Cancer
Intervention:
17 Recruiting Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
Conditions: Lymphoma;   Thorasic Cancers;   Prostate Cancer;   Leukemia
Intervention:
18 Recruiting Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
Intervention: Drug: Mithramycin
19 Not yet recruiting Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Metastatic Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Solid Neoplasm;   Stage III Mesothelioma;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
20 Recruiting 18F-FSPG PET/CT for Cancer Patients on Therapy
Conditions: B-Cell Neoplasm;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Renal Cell Cancer;   Progesterone Receptor Negative;   Stage III Mesothelioma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 L-glutamate Derivative BAY94-9392;   Procedure: Positron Emission Tomography;   Procedure: Magnetic Resonance Imaging

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.